EUVIMEDEUVIMED entdecken
Crossref

Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma

Dongzhao Xu, Fanzhang Meng, Yuan Chen, Zhimin Lin, Chen Li iD

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 16.11.2026

DOI: 10.1111/ddg.70543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 16.11.2026. Verfasst von Dongzhao Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital (Shenzhen People's Hospital), School of Medicine, Southern University of Science and Technol…. Die Arbeit nennt 17 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the short‐term clinical efficacy and safety of the Janus kinase inhibitor tofacitinib in patients with Nagashima‐type palmoplantar keratoderma (NPPK).

Methods

A retrospective analysis was performed on 7 NPPK patients with a homozygous SERPINB7 c.796C>T mutation, treated with oral tofacitinib citrate (adults: 5 mg twice daily; children: 5 mg once daily). Efficacy and adverse events were evaluated at weeks 0, 4, 8, and 12.

Results

The cohort included 5 female and 2 male patients, including 2 children. The mean age at disease onset was 15.3 years, with onset at ≤ 10 years in 5 patients. All had palmoplantar keratosis; 2 had Achilles tendon and 3 wrist involvement. All patients had ineffective prior retinoid therapy. No adverse events occurred during tofacitinib treatment. Hyperkeratosis improved markedly in 4 (57%), mildly in 1 (14%), and showed no response in 2 (29%) patients. The mean keratotic severity score decreased from 6.89 to 4.25 (approx. 40% reduction).

Conclusions

Tofacitinib may be effective for NPPK, but larger randomized controlled trials are required to confirm long‐term efficacy and safety.

Schlagwörter

Stichwörter der Autor:innen

Clinical efficacyJAK inhibitorNagashima‐type palmoplantar keratodermaSERPINB7 genetofacitinib

Autor:innen und Institutionen

  • Department of Dermatology, The First Affiliated Hospital (Shenzhen People's Hospital), School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  • Department of Rheumatology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
  • Capital Medical University Beijing Hospital of Traditional Chinese Medicine, Beijing, China.

ORCID-Profile: Chen Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xu, D., Meng, F., Chen, Y., Lin, Z., & Li, C. (2026). Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.70543

Vancouver

Xu D, Meng F, Chen Y, Lin Z, Li C. Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.70543

BibTeX
@article{Xu2026,
  author = {Xu, Dongzhao and Meng, Fanzhang and Chen, Yuan and Lin, Zhimin and Li, Chen},
  title = {Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2026},
  doi = {10.1111/ddg.70543}
}
Kostenlos starten →